Mylan Sees A Difference In Having Generic Drug User Fees
Executive Summary
FDA is pushing forward with its review of Mylan’s ANDA for generic Advair, according to the company, which is gaining confidence that the application could receive a first round approval. The experience for that application, which has a generic drug user fee, is a clear contrast to the firm's experience with its pre-GDUFA Copaxone filing.
You may also be interested in...
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'
Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection
Teva awaits district court ruling on patents covering the three-times-a-week dosage and is appealing the Patent Trial & Appeal Board’s findings of unpatentability.